$KMI: Second Take: What Kinder Morgan’s Capex Budget and Outlook …

Date: Tuesday, January 29th, 2019

Stock(s) mentioned:

Source: 24/7 Wall St. (https://247wallst.com)

Summary: When it comes to the world of oil and gas infrastructure projects and master limited partnerships (MLPs), Kinder Morgan Inc. (NYSE: KMI) remains one of the …

Full article address: https://247wallst.com/energy-business/2019/01/29/second-take-what-kinder-morgans-capex-budget-and-outlook-mean-for-natural-gas/

Related News:

$KMI: Kinder Morgan (KMI) Up 5.3% Since Last Earnings Report: Can It Continue?

$KMI: Does Kinder Morgan Canada’s Decision to Remain Independent …

$F $WDC $KMI: 3 High-Yield Dividend Stocks That Have Soared 24% or More So …

$KMI: Kinder Morgan to hold on to Canadian subsidiary

$KMI: Kinder Morgan Canada Limited Concludes Strategic Review

$KMI: Based On Its ROE, Is Kinder Morgan, Inc. (NYSE:KMI) A High Quality …

$KMI: Where Will Kinder Morgan Be in 5 Years?

$T $F $KMI: 3 High-Yield Stocks at Rock-Bottom Prices

$KMI: Insider Weekends: Long Serving Chairman Of Wireless Tower …

$KMI: Kinder Morgan’s Co-Founder Bought Millions More in Stock in One Week

$KMI: Is Kinder Morgan a Buy?

Latest News:

$SPY $BABA: If a popular options strategy suddenly implodes, be ready to scoop up cheap blue chips

$GE: Is General Electric a Buy?

$HD $URBN: Home Depot, Target, HP, Best Buy and More Major Earnings …

$TMUS: Masayoshi Son: Genius or insane? Maybe neither

$DAL $ALK $LUV $NFLX $UAL: Delta’s test of free in-flight Wi-Fi may shame other airlines into offering service

$AVTR $FSLY $LK $LYFT $PINS $UBER: Why the IPO Boom Will Continue

$SBUX: Millions of Americans Could Miss Work Tomorrow After the ‘Game of Thrones’ Finale

$AMZN $OXY $APC $WFC $SRE: Want to invest like Warren Buffett? Here are the ins and outs of buying preferred stock

$TSLA $GM: Tesla fires could dampen electric car sales as industry ramps up EV production, auto analysts say

$ROKU $GH $CVNA: 3 Stocks That Have Doubled in 2019 — Are They Still Buys?

$AXSM: Here’s Why You’ll Regret Ignoring This Biotech Stock Rocket